Arrowhead Pharma (ARWR) Price Target Raised to $115 After Trial Data

H.C. Wainwright has raised the price target for Arrowhead Pharmaceuticals (ARWR) to $115 based on new trial data. This adjustment comes as trial results indicate promising developments that could positively impact the company's valuation. Typically, price target revisions from analysts can affect investor sentiment and trading patterns. For ordinary investors, this increase suggests a potentially favorable market outlook for Arrowhead Pharmaceuticals going forward.